Advantage Investment Management’s ANI Pharmaceuticals ANIP Stock Holding History

Advantage Investment Management’s Portfolio ANIP Stock Details ANIP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$5K	Sell	62 -71	-53%	-$5.31K	﹤0.01%	752
2019 Q2	$11K	Hold	133	–	–	0.01%	639
2019 Q1	$9K	Sell	133 -115	-46%	-$6.77K	0.01%	659
2018 Q4	$11K	Buy	248 +53	+27%	+$2.78K	0.01%	630
2018 Q3	$11K	Hold	195	–	–	0.01%	681
2018 Q2	$13K	Buy	195 +133	+215%	+$8.3K	0.01%	609
2018 Q1	$4K	Hold	62	–	–	﹤0.01%	824
2017 Q4	$4K	Hold	62	–	–	﹤0.01%	840
2017 Q3	$3K	Hold	62	–	–	﹤0.01%	880
2017 Q2	$3K	Hold	62	–	–	﹤0.01%	897
2017 Q1	$3K	Hold	62	–	–	﹤0.01%	853
2016 Q4	$4K	Hold	62	–	–	﹤0.01%	766
2016 Q3	$4K	Sell	62 -2,403	-97%	-$150K	﹤0.01%	752
2016 Q2	$138K	Sell	2,465 -270	-10%	-$13.1K	0.06%	175
2016 Q1	$92K	Hold	2,735	–	–	0.04%	238
2015 Q4	$123K	Hold	2,735	–	–	0.06%	196
2015 Q3	$108K	Buy	2,735 +270	+11%	+$15.4K	0.06%	205
2015 Q2	$153K	Buy	2,465 +2,403	+3,876%	+$143K	0.07%	172
2015 Q1	$4K	Hold	62	–	–	﹤0.01%	703
2014 Q4	$4K	Buy	+62	New	+$2.73K	﹤0.01%	630

Other funds holding ANIP

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Nomura Holdings Tokyo, Japan $37.7B AUM 34.44% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ICOM

Investment Counselors of Maryland Baltimore, Maryland $4.37B AUM 76.25% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Advantage Investment Management's ANIP Position: Q3 2019 in Review

Advantage Investment Management reduced its ANI Pharmaceuticals (ANIP) stake by 53% in Q3 2019, selling an estimated $5.31K and leaving 62 shares worth $5K. The position accounts for ﹤0.01% of the portfolio, ranked #752.

Advantage Investment Management first reported a position in ANIP in Q4 2014 and has held it in 20 quarters since. The position peaked at $153K in Q2 2015. 190 funds tracked by Wall St. Rank hold ANIP as of Q3 2019.

Advantage Investment Management held 62 shares of ANI Pharmaceuticals worth $5K as of Q3 2019.
Advantage Investment Management sold 71 ANI Pharmaceuticals shares in Q3 2019, an estimated $5.31K.
ANI Pharmaceuticals made up ﹤0.01% of Advantage Investment Management's portfolio in Q3 2019, its #752 holding.
Advantage Investment Management first reported a position in ANI Pharmaceuticals in Q4 2014 and has held it in 20 quarters since.
Advantage Investment Management's ANI Pharmaceuticals position peaked at $153K in Q2 2015.
190 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q3 2019.

Based on Advantage Investment Management's 13F filing for Q3 2019, filed 8 Oct 2019.